Study identifier:1839IL/0058
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised phase II and pharmacokinetic study of oral ZD1839 given continuously with oxaliplatin or cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
head and neck cancer
Phase 2
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|